Sumatriptan in Uncontrolled Hypertension
No, sumatriptan should not be given to a patient with uncontrolled hypertension, even if their antihypertensive medications are currently being increased. This is an absolute contraindication regardless of ongoing medication adjustments.
Contraindication Status
Sumatriptan is explicitly contraindicated in patients with uncontrolled hypertension 1. This contraindication appears in:
- FDA drug labeling as a formal contraindication 1
- Clinical practice guidelines from the Headache Consortium published in Annals of Internal Medicine 2
The fact that antihypertensive medications are being titrated does not change this contraindication—the patient's blood pressure remains uncontrolled until therapeutic targets are achieved.
Mechanism of Risk
Sumatriptan causes significant cardiovascular effects through 5-HT1B/1D receptor agonism:
- Significant elevation in blood pressure, including hypertensive crisis with acute impairment of organ systems, has been reported in patients treated with triptans 1
- Sumatriptan acutely increases aortic systolic blood pressure by approximately 6 mmHg, increases aortic stiffness, and increases augmentation index by 13% 3
- The increase in aortic systolic blood pressure is larger than the increase in brachial blood pressure, meaning standard arm measurements may underestimate the true central pressure elevation 3
- These effects occur even at the lowest therapeutic doses 3
Clinical Evidence of Harm
Recent high-quality evidence demonstrates real cardiovascular risk:
- A 2024 target trial emulation study found that triptans increased the risk of major adverse cardiovascular events (MACE) 4-fold compared to non-triptan treatments (RR 4.00; 95% CI 2.24-7.14) in patients with cardiovascular disease or elevated cardiovascular risk 4
- Patients treated with triptans had significantly higher risk of nonfatal myocardial infarction, heart failure, and nonfatal stroke 4
- Case reports document sumatriptan-induced coronary artery vasospasm leading to acute ST-elevation myocardial infarction, even in patients with non-obstructive coronary arteries 5
Alternative Treatment Options
Use NSAIDs as first-line therapy instead 2:
- NSAIDs have demonstrated efficacy and favorable tolerability, making them first-line treatment for all migraine attacks 2
- Specific agents with consistent evidence include aspirin, ibuprofen, naproxen sodium, and the combination of acetaminophen plus aspirin plus caffeine 2
- NSAIDs are appropriate even for severe attacks that have responded to NSAIDs in the past 2
Consider intravenous metoclopramide 2:
- Fair evidence supports IV metoclopramide as monotherapy for acute migraine attacks 2
- Particularly useful in patients with nausea and vomiting 2
Intranasal dihydroergotamine (DHE) 2:
- Good evidence for efficacy and safety as monotherapy 2
- However, ergotamines also have vasoconstrictive properties and should be used cautiously in hypertensive patients
When Sumatriptan May Be Reconsidered
Only after blood pressure is controlled can sumatriptan be considered:
- Blood pressure must be documented as controlled on stable antihypertensive therapy before initiating triptan therapy 2
- Even in controlled hypertension, blood pressure should be monitored in patients treated with sumatriptan 1
- The first dose should ideally be administered in a medical setting for patients with cardiovascular risk factors 1
Critical Pitfall to Avoid
Do not rationalize using sumatriptan because "the blood pressure is being treated." The contraindication applies to uncontrolled hypertension, not hypertension under treatment. Until blood pressure values normalize and remain stable, the patient's hypertension remains uncontrolled and sumatriptan remains contraindicated 2, 1.